The role of endogenous and exogenous AMP in asthma and chronic obstructive pulmonary disease.

Abstract

Bronchial hyperresponsiveness is present in virtually all patients with asthma and in more than two thirds of patients with chronic obstructive pulmonary disease. Thus far, methacholine and histamine are usually used to measure bronchial hyperresponsiveness. Both are direct stimuli, because they act directly on airway smooth muscle. Another possible stimulus to measure bronchial hyperresponsiveness is AMP. AMP is an indirect stimulus, because it acts via the release of histamine and other mediators from immunologically primed mast cells. There is increasing interest in the role of AMP as a bronchoconstrictor stimulus because it has been suggested that the concentration of AMP causing the FEV 1 to decrease by 20% (PC 20 AMP) may be used as a noninvasive marker of airway inflammation. The aim of this article was to review the literature assessing AMP's value in asthma and chronic obstructive pulmonary disease.

• Authors: Maarten van den Berge, Riccardo Polosa, Huib A M Kerstjens, Dirkje S Postma
• Journal: The Journal of allergy and clinical immunology (J Allergy Clin Immunol) Vol. 114 Issue 4 Pg. 737-46 (Oct 2004) ISSN: 0091-6749 [Print] United States
• PMID: 15480309 (Publication Type: Journal Article, Review)

Chemical References

• Adrenergic beta-Agonists
• Biomarkers
• Adenosine Monophosphate

Topics

• Adenosine Monophosphate (antagonists & inhibitors, immunology)
• Adrenergic beta-Agonists (immunology, therapeutic use)
• Asthma (immunology)
• Biomarkers
• Bronchial Hyperreactivity (immunology)
• Bronchial Provocation Tests
• Humans
• Mast Cells (immunology)
• Pneumonia (immunology)
• Pulmonary Disease, Chronic Obstructive (drug therapy, immunology)